The rule was supposed to take effect Jan. 22 but is now delayed until March 22, HHS said Jan. 21. The department said the purpose of the delay is to give department officials the opportunity to further review the rule.
The rule requires all health centers receiving section 330(e) grant funds and participating in the 340B drug-pricing program to make insulin and epinephrine available to low-income patients at or below the cost the health center purchased them through the 340B drug-pricing program.
It was part of an executive order signed by former President Trump July 24 and applies to people with annual incomes at or below 350 percent of the federal poverty level who have a high cost-sharing requirement, high unmet deductible or no health insurance.
More articles on pharmacy:
Merck abandons its 2 COVID-19 vaccine candidates
FDA approves first monthly injectable to treat HIV
Amazon, Seattle health system create vaccination pop-up site
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
